Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 237
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...
Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures...
PTSF83 – Abuse in Psychedelics: Complicity and Groupthink
Addressing Abuse in Psychedelic Spaces
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol...
Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022
MYND Life Sciences Signs Agreement to Acquire Rights for the Use...
Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
Load more